In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
News|Articles|October 8, 2026
5 Years of Liver Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
Author(s)CURE staff
Fact checked by: Quincy Attobrah
Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.
Advertisement
Advertisement
Liver cancer treatment has changed a lot in five years, and how it changed tells you a lot about where it’s going. Most of the progress came in two ways: immunotherapy combinations for hepatocellular carcinoma (HCC), the most common type of liver cancer, and targeted drugs matched to the genes of bile duct cancers.
Related to this article
ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.
Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Ameluz photodynamic therapy is the first light-based treatment the FDA has approved for a skin cancer. Here's who it's for, how it works and how it compares with surgery.
The FDA has approved Pixclara, the first FET-PET imaging agent for glioma in the U.S. Here's what it does, how accurate it is and why it matters for anyone waiting on an MRI result.
Advertisement
Advertisement